New combo therapy aims to tackle rare brain cancer
NCT ID NCT07198464
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new approach for primary central nervous system lymphoma (PCNSL), a rare brain cancer. It combines CAR-T cell therapy, a stem cell transplant, and two drugs (orelabrutinib and sintilimab) to see if the mix is safe and effective. The trial plans to enroll 30 adults aged 18-60 who have not had CAR-T or stem cell transplant before. The main goals are to measure how long patients live without the cancer getting worse and how many respond to treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- relmacabtagene autoleucel (CAR-T cells), orelabrutinib, sintilimab, and autologous hematopoietic stem cell transplantation
- What this could lead to
- If successful, this combination could offer a more effective treatment option for primary central nervous system lymphoma, potentially improving survival and response rates.
- What could go wrong
- This is a small, early-phase study with only 30 participants, so results may not apply to everyone. The combination therapy carries risks of serious side effects, including immune reactions and infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY CENTRAL NERVOUS SYSTEM DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New cocktail aims to shrink brain tumors
- Real-World data shows Tirabrutinib's promise for rare brain cancer
- New cocktail of drugs shows promise for deadly brain cancer
- New drug takes aim at Hard-to-Treat blood cancers
- Promising cocktail targets brain cancer
- New hope for brain cancer patients: drug may stop relapse